Suven Life Sciences Limited (SUVEN.BO)
INR 121.7
(2.4%)
INR 121.7
(2.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -200.79 Million INR | -67.43% |
| 2022 | -119.92 Million INR | 12.66% |
| 2021 | -137.3 Million INR | -45.63% |
| 2020 | -94.28 Million INR | -6.92% |
| 2019 | -88.17 Million INR | -105.63% |
| 2018 | 1.56 Billion INR | -57.71% |
| 2017 | 3.7 Billion INR | 21.23% |
| 2016 | 3.05 Billion INR | 30.61% |
| 2015 | 2.34 Billion INR | -15.09% |
| 2014 | 2.75 Billion INR | -13.82% |
| 2013 | 3.19 Billion INR | 134.95% |
| 2012 | 1.36 Billion INR | 33.85% |
| 2011 | 1.01 Billion INR | 6.55% |
| 2010 | 954.69 Million INR | 35.57% |
| 2009 | 704.2 Million INR | -4.09% |
| 2008 | 734.2 Million INR | 23.55% |
| 2007 | 594.25 Million INR | 1.85% |
| 2006 | 583.47 Million INR | 20.15% |
| 2005 | 485.63 Million INR | 31.52% |
| 2004 | 369.24 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -60.78 Million INR | 14.46% |
| 2024 Q1 | -71.06 Million INR | -66.24% |
| 2023 FY | -200.79 Million INR | -67.43% |
| 2023 Q4 | -42.74 Million INR | 30.76% |
| 2023 Q1 | -48.92 Million INR | -14.08% |
| 2023 Q3 | -61.73 Million INR | -30.26% |
| 2023 Q2 | -47.39 Million INR | 3.13% |
| 2022 Q3 | -44.03 Million INR | -10.82% |
| 2022 FY | -119.92 Million INR | 12.66% |
| 2022 Q2 | -39.73 Million INR | 9.91% |
| 2022 Q4 | -42.88 Million INR | 2.61% |
| 2022 Q1 | -44.1 Million INR | 17.73% |
| 2021 Q1 | -50.88 Million INR | -449.97% |
| 2021 FY | -137.3 Million INR | -45.63% |
| 2021 Q4 | -53.61 Million INR | -47.75% |
| 2021 Q3 | -36.28 Million INR | 42.74% |
| 2021 Q2 | -63.36 Million INR | -24.53% |
| 2020 Q1 | 14.28 Million INR | -83.46% |
| 2020 Q2 | 89.79 Million INR | 528.56% |
| 2020 Q3 | 15.13 Million INR | -83.15% |
| 2020 Q4 | 14.54 Million INR | -3.9% |
| 2020 FY | -94.28 Million INR | -6.92% |
| 2019 Q4 | 86.37 Million INR | 211.52% |
| 2019 FY | -88.17 Million INR | -105.63% |
| 2019 Q3 | 27.72 Million INR | 102.36% |
| 2019 Q1 | -650.93 Million INR | -131.4% |
| 2019 Q2 | -1.17 Billion INR | -80.19% |
| 2018 Q4 | 2.07 Billion INR | 12571.4% |
| 2018 Q1 | 1.04 Billion INR | 0.0% |
| 2018 Q3 | 16.35 Million INR | -97.22% |
| 2018 Q2 | 588.18 Million INR | -43.58% |
| 2018 FY | 1.56 Billion INR | -57.71% |
| 2017 FY | 3.7 Billion INR | 21.23% |
| 2016 FY | 3.05 Billion INR | 30.61% |
| 2016 Q4 | 1.34 Billion INR | 0.0% |
| 2015 Q3 | 568.41 Million INR | -30.99% |
| 2015 Q4 | 1.2 Billion INR | 111.57% |
| 2015 FY | 2.34 Billion INR | -15.09% |
| 2015 Q2 | 823.69 Million INR | 44.73% |
| 2015 Q1 | 569.12 Million INR | 2.73% |
| 2014 Q2 | 783.7 Million INR | -2.84% |
| 2014 Q1 | 806.6 Million INR | 11.38% |
| 2014 FY | 2.75 Billion INR | -13.82% |
| 2014 Q4 | 554.02 Million INR | -27.84% |
| 2014 Q3 | 767.81 Million INR | -2.03% |
| 2013 Q1 | 631.82 Million INR | 80.37% |
| 2013 Q4 | 724.2 Million INR | -10.04% |
| 2013 Q3 | 804.99 Million INR | -22.45% |
| 2013 FY | 3.19 Billion INR | 134.95% |
| 2013 Q2 | 1.03 Billion INR | 64.29% |
| 2012 Q3 | 363.38 Million INR | 32.12% |
| 2012 Q4 | 350.28 Million INR | -3.6% |
| 2012 FY | 1.36 Billion INR | 33.85% |
| 2012 Q1 | 457.72 Million INR | 0.0% |
| 2012 Q2 | 275.04 Million INR | -39.91% |
| 2011 FY | 1.01 Billion INR | 6.55% |
| 2010 FY | 954.69 Million INR | 35.57% |
| 2009 FY | 704.2 Million INR | -4.09% |
| 2008 FY | 734.2 Million INR | 23.55% |
| 2007 FY | 594.25 Million INR | 1.85% |
| 2006 FY | 583.47 Million INR | 20.15% |
| 2005 FY | 485.63 Million INR | 31.52% |
| 2004 FY | 369.24 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 100.75% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 100.13% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 101.615% |
| Granules India Limited | 16.79 Billion INR | 101.195% |
| Indoco Remedies Limited | 6.04 Billion INR | 103.324% |
| Achyut Healthcare Limited | 4.86 Million INR | 4230.776% |
| Ajanta Pharma Limited | 21.06 Billion INR | 100.953% |
| Alkem Laboratories Limited | 52.29 Billion INR | 100.384% |
| Alpa Laboratories Limited | 188.89 Million INR | 206.301% |
| Brooks Laboratories Limited | 65.62 Million INR | 406.0% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 103.227% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 113.643% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 105.434% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 100.123% |
| Eris Lifesciences Limited | 10.42 Billion INR | 101.926% |
| FDC Limited | 8.33 Billion INR | 102.409% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 100.29% |
| Gufic Biosciences Limited | 4.16 Billion INR | 104.818% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 103.242% |
| Ipca Laboratories Limited | 29.8 Billion INR | 100.674% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 130.769% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | 204.187% |
| Lasa Supergenerics Limited | 121.02 Million INR | 265.907% |
| Laurus Labs Limited | 24.62 Billion INR | 100.816% |
| Lupin Limited | 123.71 Billion INR | 100.162% |
| Mankind Pharma Limited | 44.52 Billion INR | 100.451% |
| Medicamen Biotech Limited | 495.49 Million INR | 140.525% |
| Medico Remedies Limited | 262.14 Million INR | 176.598% |
| Megasoft Limited | 342.07 Million INR | 158.7% |
| NATCO Pharma Limited | 25.73 Billion INR | 100.78% |
| Piramal Pharma Limited | 24.47 Billion INR | 100.821% |
| RPG Life Sciences Limited | 2.48 Billion INR | 108.087% |
| Sigachi Industries Limited | 2 Billion INR | 110.028% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 100.078% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 104.87% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 121.307% |
| Unichem Laboratories Limited | 4.86 Billion INR | 104.127% |
| Wanbury Limited | 1.73 Billion INR | 111.602% |
| Windlas Biotech Limited | 1.33 Billion INR | 114.998% |
| ZIM Laboratories Limited | 1.26 Billion INR | 115.85% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 100.16% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 66.667% |
| Divi's Laboratories Limited | 32.44 Billion INR | 100.619% |
| Hester Biosciences Limited | 1.27 Billion INR | 115.765% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 103.473% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 112.9% |
| Bal Pharma Limited | 770.19 Million INR | 126.071% |
| Strides Pharma Science Limited | 14.38 Billion INR | 101.396% |
| Venus Remedies Limited | 2.18 Billion INR | 109.2% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 103.443% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 106.756% |
| Shilpa Medicare Limited | 3.54 Billion INR | 105.661% |
| Aarti Drugs Limited | 8.31 Billion INR | 102.415% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 104.383% |
| Ind-Swift Limited | 2.17 Billion INR | 109.243% |
| Valiant Laboratories Limited | -60.66 Million INR | -230.999% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 100.885% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 123.316% |
| Themis Medicare Limited | 1.5 Billion INR | 113.352% |
| Hikal Limited | 3.14 Billion INR | 106.389% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 100.429% |
| Sequent Scientific Limited | 2.97 Billion INR | 106.741% |
| Novartis India Limited | 1.32 Billion INR | 115.133% |
| Wockhardt Limited | 16.24 Billion INR | 101.236% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 101.022% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | 1477.237% |
| Neuland Laboratories Limited | 8.24 Billion INR | 102.435% |
| Morepen Laboratories Limited | 6.16 Billion INR | 103.259% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 132.362% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 128.538% |